TQB2440

· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for TQB2440, covering 2023-08-14 to 2023-08-14. Get the full timeline:

Most recent: Clinical Trial Update: Clinical Study to Evaluate the Efficacy and Safety of TQB2440 Injection/Perjeta® Combined With Trastuzumab and Docetaxel in the Treatment of Patients With Early or Locally Advanced Breast Cancer. [Phase 3]

See pricing